BRIEF-Editas Medicine Inc - Nominates Edit-401 As Lead In Vivo Candidate
Reuters
Sep 02
BRIEF-Editas Medicine Inc - Nominates Edit-401 As Lead In Vivo Candidate
Editas Medicine Inc EDIT.O:
EDITAS MEDICINE INC - NOMINATES EDIT-401 AS LEAD IN VIVO CANDIDATE
EDITAS MEDICINE INC - EDIT-401 ON TRACK FOR HUMAN PROOF-OF-CONCEPT DATA BY END OF 2026
EDITAS MEDICINE INC - TO SUBMIT IND OR CTA FOR EDIT-401 BY MID-2026
Source text: ID:nGNX71kqvq
Further company coverage: EDIT.O
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.